Efficacy of lidocaine–prilocaine combined with amitriptyline or Acmella oleracea in a liposomal cream for topical anesthesia: a randomized crossover clinical trial Authors: Michael Henrique Araujo Monteiro, Josilanny Araujo de Souza Alencar, Victor Augusto Benedicto dos Santos, Francisco Carlos Groppo, Camila Batista da Silva de Araujo Candido, Sidney Raimundo Figueroba Published: 2025 ABSTRACT AbstractBackgroundPain remains one of the main causes of apprehension during dental procedures. In this context, topical anesthetics play an essential role in reducing discomfort, and new compounds such as amitriptyline and jambu (Acmella oleracea) extract have been investigated as promising alternatives. Drug delivery systems, such as Pentravan®, a nanosomal transdermal base, are also of interest; however, their application on oral mucosa has not yet been clinically evaluated. Therefore, this study aimed to compare the anesthetic efficacy of lidocaine (LDC) and prilocaine (PLC) combined with either amitriptyline or jambu, formulated as ointments or incorporated into Pentravan®, for topical anesthesia of the buccal and palatal mucosa of maxillary premolars, using pulpal response and puncture sensitivity as outcome measures.MethodsA randomized, blinded, crossover clinical trial was conducted with 40 healthy volunteers who received six formulations: (1) LDC 2.5% + PLC 2.5% (positive control); (2) LDC 2.5% + PLC 2.5% + amitriptyline 5%; (3) LDC 2.5% + PLC 2.5% + jambu extract 20% (7.5% spilanthol); (4) LDC 2.5% + PLC 2.5% + amitriptyline 5% in Pentravan®; (5) LDC 2.5% + PLC 2.5% + jambu extract 20% in Pentravan®; and (6) base ointment without active ingredients (placebo). Pain upon needle puncture was assessed using the visual analog scale, and pulpal anesthesia was evaluated with an electric pulp tester.ResultsFormulations 1 and 2 produced the lowest pain scores in the buccal mucosa, with Formulation 1 showing statistically superior results than Formulations 3, 4, 5, and 6 (P < 0.05). Formulation 6 yielded the highest pain scores, while Formulations 2–5 demonstrated intermediate efficacy without significant differences. Formulations 1 and 2 were also the most effective on the palatal mucosa. None of the formulations achieved significant pulpal anesthesia. Adverse effects were mild and self-limiting, with mucosal desquamation observed only with Formulation 2.ConclusionAmitriptyline demonstrated relevant clinical potential, whereas jambu extract showed intermediate efficacy. Pentravan®-based formulations did not exhibit clinical superiority. Future studies should focus on optimizing these combined formulations to enhance the efficacy of topical anesthesia in dentistry.Keywords: Acmella; Amitriptyline; Anesthesia, Local; Excipients; Lidocaine; Prilocaine INTRODUCTION Pain remains one of the main causes of apprehension during dental procedures and is often associated with negative childhood experiences or the tendency to seek care only when pain becomes severe [1,2]. To minimize this discomfort, modern dentistry has advanced through the use of local anesthetics and, complementarily, topical anesthetics, which are indicated to alleviate painful stimuli during procedures such as needle punctures, simple extractions of deciduous teeth, and chronic pain management [3]. These drugs are well recognized for their efficacy and safety, as they are minimally absorbed and rarely cause systemic adverse reactions when used properly [4]. Among the most widely used local anesthetics in dentistry are lidocaine (LDC) and prilocaine (PLC), which are often associated in topical formulations [5]. Compounds originally developed for other pharmacological purposes have been explored to enhance the effectiveness of topical anesthesia. Amitriptyline, a first-generation tricyclic antidepressant derived from dibenzosuberenone, inhibits the reuptake of serotonin and norepinephrine and has affinity for 5-HT2C and α1 receptors [6]. Its interaction with sodium and potassium channels provides a mechanism similar to that of local anesthetics, making it a promising candidate for topical formulations [7]. Evidence has indicated favorable results with amitriptyline in mucoadhesive and gel formulations for analgesia in reversible pulpitis and during dental procedures [8,9]. Another compound under investigation is Acmella oleracea (A. oleracea), commonly known as jambu, a member of the Asteraceae family. Traditionally used in the northern region of Brazil for dental pain relief, this plant is popularly called the “toothache plant” [10]. Its analgesic action involves the inhibition of prostaglandin synthesis, similar to the mechanism of nonsteroidal anti-inflammatory drugs [11]. The main bioactive compound of jambu, spilanthol, has demonstrated topical anesthetic effects on the oral mucosa [12,13]. In this context, liposomes and Pentravan® (Fagron, Brazil) stand out as nanosomal transdermal vehicles widely used in pharmaceutical formulations, particularly in hormonal and analgesic therapies, for their ability to enhance drug penetration and stability [14,15,16]. Therefore, this study seeks to evaluate whether the combination of LDC and PLC with either amitriptyline or jambu, delivered in a conventional base or incorporated into Pentravan®, can optimize topical anesthesia and reduce discomfort during dental procedures. Additionally, the study investigates whether penetration-enhancing vehicles can deepen the anesthetic action to the extent of influencing pulpal sensitivity, an effect not typically achieved by conventional topical formulations. METHODS This randomized, double-blind, crossover clinical trial employed a split-mouth design. The study was approved by the Research Ethics Committee of the Faculdade de Odontologia de Piracicaba (FOP), Universidade Estadual de Campinas (UNICAMP) (CAAE: 7.225.939) and registered in the Brazilian Registry of Clinical Trials (https://ensaiosclinicos.gov.br/rg/RBR-10kn9x8f). All participants provided written informed consent before inclusion. Participants were recruited between August and November 2024, and all follow-up assessments were completed within this period. 1. Sample size calculation and selection criteria Based on previous studies [17,18,19], a minimum detectable difference of 10 units in the mean puncture pain score between groups was estimated, assuming a standard deviation of 4 on the visual analog scale (VAS). The sample size calculation indicated 40 participants were required to achieve 80% statistical power (β = 20%) at a 5% significance level. An additional 20% was included to account for the subjective nature of pain assessment, resulting in a final sample of 40 volunteers. Inclusion criteria were healthy individuals aged 18–40 years, enrolled at FOP-UNICAMP, with clinically and radiographically healthy maxillary premolars (teeth #14 and #24), a positive response to an electric pulp tester (EPT), previous experience with local anesthesia, and no history of adverse reactions. Exclusion criteria included pregnancy or lactation; patients with systemic conditions contraindicating topical anesthesia; use of antidepressants, anticonvulsants, or anti-inflammatory drugs; presence of local inflammation; or direct involvement in the research project. The final sample consisted of undergraduate (2nd–5th year) and postgraduate students of both sexes who did not require dental intervention during the study. 2. Randomization and experimental design The crossover design ensured that each of the 40 participants received all six experimental formulations, allowing each individual to serve as their own control. The application sequence of the formulations was determined individually through randomization using Microsoft Excel 365 with the formula =INDEX (RANK.EQ(A1:A6, RANDARRAY(6)), SEQUENCE (6)). The six formulations were administered over three study periods, with two formulations applied simultaneously per period: one to the buccal mucosa and the other to the palatal mucosa, specifically in the region of teeth #14 and #24 (the right and left maxillary first premolars, respectively). To ensure that the randomization of the overall sequence allowed each formulation to be tested on both sides across the entire sample, one formulation was applied to the vestibular mucosa of the right first premolar and another to the left first premolar. Participant flow throughout the trial is presented in the Consolidated Standards of Reporting Trials (CONSORT) diagram (Fig. 1), adapted from the CONSORT 2025 statement [20]. Flowchart of the randomized, crossover, double-blind, split-mouth clinical trial. All 40 randomized participants received all six topical formulations in a random order, ensuring that each participant served as their own control. The study was conducted across three periods with a 7-day washout interval between periods. In each period, two formulations were applied simultaneously in a split-mouth design on the right and left sides of the maxilla. The first formulation of the randomized pair was applied to the right first maxillary premolar (#14), and the second formulation was applied to the left first maxillary premolar (#24), thus ensuring that the randomization of the overall sequence allowed all formulations to be tested on both sides across the entire sample. Data from all 40 volunteers were included in the final analysis for each of the six formulations. 3. Tested formulations and preparation Six topical formulations were evaluated in this study: (1) LDC 2.5% combined with PLC 2.5% (EMLA®, Aspen Pharma, Brazil); (2) LDC 2.5%, PLC 2.5%, and amitriptyline 5% incorporated into an ointment base; (3) LDC 2.5%, PLC 2.5%, and 20% jambu extract standardized to 7.5% spilanthol in ointment base; (4) LDC 2.5%, PLC 2.5%, and amitriptyline 5% incorporated into Pentravan®; (5) LDC 2.5%, PLC 2.5%, and 20% jambu extract in Pentravan®; and (6) base ointment without active pharmaceutical ingredients, used as a placebo. The following substances were used: EMLA® 5%, Pentravan®, LDC hydrochloride, PLC hydrochloride (Sigma-Aldrich, USA), and amitriptyline hydrochloride (Via Farma, Brazil). The ethanolic extract of jambu (A. oleracea) containing a standardized concentration of 7.5% spilanthol was supplied by the Multidisciplinary Center for Chemical, Biological, and Agricultural Research (CPBQA/UNICAMP, Brazil). An EPT (Vitality Scanner, model 2006; Analytic Technology, USA) was used to assess pulpal anesthesia, and a 25 mm, 30G short needle (Jets; GN Injecta Ind. Com. Mat. Med. Cirurg. Odont. E descart. Ltda, Ibiporã, PR, Brazil) was used to evaluate mucosa sensibility using the VAS. The base ointment was prepared at the Pharmacology Laboratory of FOP-UNICAMP and contained beeswax (30%), castor oil (5%), and liquid vaseline (65%), following a standardized heating and stirring protocol to ensure homogeneity, stability, and biocompatibility. The active ingredients were incorporated under aseptic conditions by a pharmacy graduate, independent of the clinical team, at the beginning of the clinical phase. All formulations were stored in opaque bottles and coded numerically (1–6) to ensure participant blinding. 4. Clinical procedure and evaluation The formulations were applied using sterile gauze in a standardized amount of 100 mg [18]. To maintain contact for 5 min [20,21], a small sterile gauze pad was placed over the buccal and palatal mucosa and held with gentle digital pressure, with saliva isolation and suction as needed (Fig. 2A). After 5 min, any excess material was removed using dry gauze. Subsequently, a simulated puncture was performed using a carpule syringe and a 25 mm, 30G short needle until contact with the periosteum was achieved (Fig. 2C–F). Participants rated the puncture’s pain intensity on the VAS, ranging from 0 (no pain) to 10 (worst possible pain). Afterwards, they completed a questionnaire regarding discomfort and any adverse effects. Clinical procedure for evaluating the efficacy of topical anesthetic formulations. (A) Application of the topical formulation on the buccal and palatal mucosa of both the right and left sides of the maxilla. (B) Pulp sensitivity assessment using an electric pulp tester (EPT). (C) Simulated puncture on the right buccal mucosa. (D) Simulated puncture on the right palatal mucosa. (E) Simulated puncture on the left buccal mucosa. (F) Simulated puncture on the left palatal mucosa. Pulpal anesthesia was assessed via electrical stimulation of teeth #14 and #24 every 2 min for 20 min, with three repetitions per time point. The absence of a response at maximum intensity (80 units) was considered indicative of anesthesia [22]. The probe tip was positioned on the facial surface with conductive gel [23]. The onset time of anesthesia was defined as the interval between the end of topical application and the first absence of a response to the maximum stimulus. The duration was recorded until the baseline response returned. Immediately after the procedure, each participant received an adverse event reporting form and was instructed to record the type and duration of any abnormal sensations, including the perception of numbness, during the 48-h monitoring period. “Prolonged anesthesia” was defined as an adverse event if the participant reported numbness in the application area for a period exceeding 60 min after gauze removal. All applications and punctures were performed by the same researcher, and adverse events were monitored for 48 h. 5. Statistical analysis EPT values were analyzed by curve comparison using the slope estimation through linear regression. Pain perception recorded on the VAS was evaluated using the Friedman test, followed by the Benjamini, Krieger, and Yekutieli (BKY) post hoc test. Reported adverse effects were tabulated according to the tested formulation. All statistical analyses and graph generations were performed using GraphPad Prism 8.0 for Windows (GraphPad Software, USA). Statistical significance was set at P < 0.05. RESULTS The sample consisted of 40 participants (20 males and 20 females). No statistically significant difference was observed in the mean age between the groups, with averages of 24.3 ± 3.2 years for men and 24.2 ± 2.6 years for women (unpaired t-test; P = 0.91). 1. Sensitivity to puncture Fig. 3 shows pain perception measured using the VAS (median, lower–upper confidence limits), for both the vestibular and palatal mucosa. The Friedman and BKY post hoc tests revealed that Formulation 1 (0, 0–4.6) produced significantly lower VAS scores in the vestibular mucosa than Formulations 3 (5.0, 0–13.7; P = 0.0422), 4 (6.6, 0–16.1; P = 0.0422), 5 (3.2, 0–16.3; P = 0.0320), and 6 (18.9, 12.0–30.4; P < 0.0001), but did not differ from Formulation 2 (1.7, 0–6.4; P = 0.39). Formulations 2, 3, 4, and 5 did not differ significantly from each other (P > 0.05), but all showed significantly lower VAS scores than Formulation 6 (P < 0.05). The VAS values (median, lower–upper confidence limits) obtained after puncture in the palatal mucosa showed no statistically significant differences (P = 0.09) between Formulations 1 (2.7, 0– 12.1) and 2 (11.4, 5.2–21.7), although both had significantly lower VAS scores (P < 0.05) than the other formulations. Formulations 3 (17.8, 9.2–27.2), 4 (26.2, 12.5–38.7), 5 (19.8, 13.0–44.8), and 6 (20.5, 13.2–54.1) exhibited no statistically significant differences among themselves (P > 0.05). Pain perception measured using the visual analog scale. (A) Visual analog scale (VAS) scores on the buccal mucosa. (B) VAS scores on the palatal mucosa. The center line represents the median, the box indicates the 1st and 3rd quartiles, whiskers denote the minimum and maximum values, and the + symbol represents the mean. Different letters indicate statistically significant differences (P < 0.05). Formulations were as follows: (1) EMLA® (lidocaine [LDC] 2.5% + prilocaine [PLC] 2.5%); (2) LDC 2.5% + PLC 2.5% + amitriptyline 5%; (3) LDC 2.5% + PLC 2.5% + jambu (Acmella oleracea) extract 20%; (4) LDC 2.5% + PLC 2.5% + amitriptyline 5% in Pentravan®; (5) LDC 2.5% + PLC 2.5% + jambu extract 20% in Pentravan®; and (6) base ointment without active ingredients (placebo). Data were collected from all 40 participants for each formulation. 2. Pulpal anesthesia The values (Fig. 4) were analyzed by linear regression, and the curves were compared pairwise using the EPT values obtained over 20 min for each formulation. The analysis revealed no statistically significant differences (P > 0.05) between the slopes of the curves, indicating that the progression of the EPT values obtained over 20 min did not differ among the formulations. Therefore, none of the formulations altered pulpal sensitivity to electrical stimulation. Electric pulp tester values over time (min) for each formulation. The letter “B” represents the baseline pulpal value before intervention. Data are presented as mean ± standard deviation of the values obtained with the electric pulp tester (EPT) over 20 min for each formulation. The dashed line represents linear regression. Formulations were as follows: (1) EMLA® (lidocaine [LDC] 2.5% + prilocaine [PLC] 2.5%); (2) LDC 2.5% + PLC 2.5% + amitriptyline 5%; (3) LDC 2.5% + PLC 2.5% + jambu (Acmella oleracea) extract 20%; (4) LDC 2.5% + PLC 2.5% + amitriptyline 5% in Pentravan®; (5) LDC 2.5% + PLC 2.5% + jambu extract 20% in Pentravan®; and (6) base ointment without active ingredients (placebo). Data were collected from all 40 participants for each formulation. 3. Adverse effects Table 1 presents the cumulative number of adverse effects reported by participants within 48 h after the application of each formulation. Formulations 1 and 2 accounted for the highest number of reported events. Desquamation of the vestibular mucosa was observed exclusively in Formulation 2, whereas episodes of prolonged mucosal anesthesia were reported for all formulations containing active ingredients, particularly Formulations 1, 4, and 5. Isolated cases of aphthae, lip edema, mild discomfort, local erythema, sensory changes (tingling or burning), and reactions related to the product’s taste or odor were also reported. Formulation 6 exhibited the lowest number of adverse effects, with only one reported case of lip edema. Table 1Cumulative number of adverse effects reported within 48 h following the interventionsAdverse eventFormulations n (%)*†123456At least one adverse event7 (17.5)14 (35)7 (17.5)4 (10)3 (7.5)1 (2.5)No clinical alterations observed33 (82.5)26 (65)33 (82.5)36 (90)37 (92.5)39 (97.5)Mucosal desquamation-13 (32.5)----Prolonged anesthesia of the vestibular mucosa4 (10)2 (5)1 (2.5)3 (7.5)3 (7.5)-Aphthous ulceration1 (2.5)2 (5)----Labial edema1 (2.5)1 (2.5)---1 (2.5)Mild discomfort1 (2.5)-----Localized erythema--2 (5)-1 (2.5)-Unpleasant taste during application1 (2.5)-3 (7.5)2 (5)--Unpleasant odor during application--1 (2.5)1 (2.5)--Burning sensation during application--1 (2.5)1 (2.5)--Tingling sensation after procedure--1 (2.5)---Description of the cumulative number of adverse effects observed for each formulation within 48 h. Forty volunteers received each formulation. Formulations: (1) EMLA® (lidocaine [LDC] 2.5% + prilocaine [PLC] 2.5%); (2) LDC 2.5% + PLC 2.5% + amitriptyline 5%; (3) LDC 2.5% + PLC 2.5% + jambu (Acmella oleracea) extract 20%; (4) LDC 2.5% + PLC 2.5% + amitriptyline 5% in Pentravan®; (5) LDC 2.5% + PLC 2.5% + jambu extract 20% in Pentravan®; and (6) base ointment without active ingredients (placebo).*Percentages were calculated using the total number of participants per formulation (N = 40).†Participants could report more than one specific adverse effect; therefore, column totals for specific events may exceed 100%, whereas “At least one adverse event” represents participants reporting any adverse effect. Cumulative number of adverse effects reported within 48 h following the interventions Description of the cumulative number of adverse effects observed for each formulation within 48 h. Forty volunteers received each formulation. Formulations: (1) EMLA® (lidocaine [LDC] 2.5% + prilocaine [PLC] 2.5%); (2) LDC 2.5% + PLC 2.5% + amitriptyline 5%; (3) LDC 2.5% + PLC 2.5% + jambu (Acmella oleracea) extract 20%; (4) LDC 2.5% + PLC 2.5% + amitriptyline 5% in Pentravan®; (5) LDC 2.5% + PLC 2.5% + jambu extract 20% in Pentravan®; and (6) base ointment without active ingredients (placebo). *Percentages were calculated using the total number of participants per formulation (N = 40). †Participants could report more than one specific adverse effect; therefore, column totals for specific events may exceed 100%, whereas “At least one adverse event” represents participants reporting any adverse effect. 4. pH of the formulations The formulations were analyzed at room temperature using a calibrated pH meter, as described in the Methodology section, and Table 2 presents the results. Formulation 1 had the most alkaline pH (8.84), while the other formulations ranged from 3.90 to 5.71. Formulation 4 had the lowest pH (3.90), followed by that of Formulation 5 (4.35). Formulation 6 had a slightly acidic pH of 5.48, which was higher than that of the Pentravan®-based formulations and Formulation 3. Table 2pH values of the topical formulations used in the studyTopical formulations123456pH8.845.714.953.94.355.48pH values of the topical formulations. Formulations: (1) EMLA® (lidocaine [LDC] 2.5% + prilocaine [PLC] 2.5%); (2) LDC 2.5% + PLC 2.5% + amitriptyline 5%; (3) LDC 2.5% + PLC 2.5% + jambu (Acmella oleracea) extract 20%; (4) LDC 2.5% + PLC 2.5% + amitriptyline 5% in Pentravan®; (5) LDC 2.5% + PLC 2.5% + jambu extract 20% in Pentravan®; and (6) base ointment without active ingredients (placebo). pH values of the topical formulations used in the study pH values of the topical formulations. Formulations: (1) EMLA® (lidocaine [LDC] 2.5% + prilocaine [PLC] 2.5%); (2) LDC 2.5% + PLC 2.5% + amitriptyline 5%; (3) LDC 2.5% + PLC 2.5% + jambu (Acmella oleracea) extract 20%; (4) LDC 2.5% + PLC 2.5% + amitriptyline 5% in Pentravan®; (5) LDC 2.5% + PLC 2.5% + jambu extract 20% in Pentravan®; and (6) base ointment without active ingredients (placebo). DISCUSSION This randomized, double-blind, crossover, split-mouth clinical study evaluated the effects of different topical formulations on pulpal sensitivity, pain perception upon puncture, and the occurrence of adverse events. The results revealed significant differences among the formulations in both participant-reported pain and observed adverse effects. On the buccal mucosa, Formulation 1 (EMLA®) produced the lowest pain scores, demonstrating statistical superiority over the other formulations, except Formulation 2 (with amitriptyline), with which it showed no significant difference. These findings confirm the efficacy of EMLA®, corroborating previous studies [24,25,26]. Formulations containing amitriptyline (2 and 4) or jambu (3 and 5) exhibited intermediate anesthetic effects without significant differences between them, while the placebo (Formulation 6) yielded the highest pain scores, confirming the absence of anesthetic action, as also reported by Ribeiro et al. [3]. A different pattern was observed in the palatal mucosa, where Formulations 1 and 2 were more effective than the other formulations, producing significantly lower pain scores. This difference may be attributed to the lower permeability of the palatal mucosa, which is thicker and more keratinized, thus limiting the diffusion of topical anesthetics [27]. Although not approved as an anesthetic, topical amitriptyline has demonstrated local action by blocking sodium channels [9], with a peak effect occurring between 9 and 25 min [8]. This pharmacodynamic profile may explain its positive performance in this study, particularly on the palatal mucosa. The 5-min application time, while potentially insufficient to achieve maximum anesthetic efficacy, was selected to reflect realistic clinical conditions, where longer waiting periods are impractical. This time constraint may have impacted the results, particularly for the palatal mucosa, given its greater thickness and lower permeability. Jambu, whose main active compound is spilanthol, possesses antinociceptive properties attributed to TRPV1/TRPA1 channel modulation and increased gamma-aminobutyric acid release [28,29]. Despite its previously demonstrated clinical potential in other applications [13,30,31], the jambu-containing formulations (3 and 5) did not show anesthetic superior performance, which may indicate limitations in bioavailability, stability, or the time required to achieve clinical efficacy in the oral mucosa. The comparison between vehicles also revealed important differences. Although Formulations 4 and 5 contained the same active ingredients as Formulations 2 and 3, respectively, but were delivered in Pentravan®, they did not demonstrate clinical superiority. This may be attributed to their acidic pH values (3.90 and 4.35), which can reduce the non-ionized fraction of local anesthetics and hinder their diffusion across neuronal membranes [14,15,32]. Additionally, Pentravan®, although effective in other routes of administration, may not have provided adequate drug release or adhesion to the oral mucosa. Regarding anesthetic depth, no formulation promoted significant pulpal anesthesia, contradicting the initial hypothesis that vehicles such as Pentravan®, when combined with amitriptyline or jambu, could potentiate tissue diffusion. The absence of pulpal blockade suggests limited penetration of the active ingredients, consistent with previous findings using ropivacaine and benzocaine encapsulated in liposomes [17,33]. Therefore, the application of these agents should be focused on soft tissues, where they demonstrate greater clinical efficacy [5,27]. Our findings, showing that the most effective formulations (1 and 2) significantly reduced puncture pain, validate their important adjunctive role before infiltration anesthesia [25,27]. Beyond this primary indication, their mucosal efficacy supports their potential use as sole anesthetic agents for various superficial dental procedures, including periodontal probing, scaling, and root planing [34], clamp placement [35], gingival retraction [36], and the extraction of mobile deciduous teeth [37]. Formulation 2 did not differ significantly from Formulation 1 but was superior to the other formulations. Therefore, the formulation containing amitriptyline may represent a viable alternative to the eutectic formulation of PLC and LDC. (EMLA®). Adverse events, such as bitter taste, burning, and mild local discomfort, were generally mild and self-limiting. Formulation 2 produced the highest number of adverse reactions, including mucosal desquamation. This adverse event was short-lived and self-limiting, with both onset and spontaneous resolution occurring within the first 48 h post-application, consistent with previous reports on the topical use of amitriptyline [8]. Formulation 4, containing the same active ingredients but delivered in Pentravan®, did not exhibit the same side effects, suggesting that the vehicle may influence the safety profile. EMLA® demonstrated good tolerability, with few reports of isolated aphthae or edema, corroborating studies that support its efficacy and describe its adverse effects as mild and reversible [19,25,38]. Another relevant finding was the occurrence of prolonged anesthesia in the buccal mucosa for Formulations 1–5, indicating a sustained anesthetic effect. This is consistent with the synergistic action of LDC and PLC in EMLA®, and suggests that the addition of amitriptyline or jambu may further prolong the anesthetic effect. However, Formulation 3 (jambu + base ointment) showed a lower incidence of prolonged anesthesia, which may indicate a shorter duration of the anesthetic action of jambu when delivered with Pentravan®. Among the limitations of this study, the absence of anesthetic solution deposition is notable, as this differs from typical clinical practice and may have limited the simulation of real pain during invasive procedures. Additionally, the short application duration may have been insufficient for active ingredients, such as amitriptyline and spilanthol, to achieve maximum efficacy. Finally, the sample consisting exclusively of young, healthy university students, while ideal for controlling variables, limits the generalizability of the findings to broader populations, including older adults, pediatric patients, and patients with systemic comorbidities. Future studies should explore longer application times, pH optimization, and the use of permeation-enhancing strategies, as well as assess across different mucosal regions, diverse patient populations, and actual dental procedures. The findings of this clinical trial indicate that EMLA® cream was the most effective formulation for reducing pain upon puncture in both the buccal and palatal mucosa, reinforcing its position as the gold standard in topical dental anesthesia. The combination of LDC, PLC, and amitriptyline in ointment demonstrated comparable performance to EMLA® on the palatal mucosa, suggesting potential clinical applicability. The formulations containing jambu produced an intermediate anesthetic effect, superior to the placebo and comparable to amitriptyline in some parameters, supporting continued investigation of this compound. The use of Pentravan® did not confer additional clinical benefit, possibly due to its acidic pH, which may have compromised the diffusion of anesthetics through the oral mucosa. Finally, none of the evaluated formulations promoted pulpal anesthesia, restricting their anesthetic effects to the soft tissues under the conditions of this study. These results reinforce that the primary clinical role of these topical agents is to enhance patient comfort, serving as a valuable adjunct to injectable anesthesia, which remains essential for most dental procedures. ACKNOWLEDGEMENTS The authors express their gratitude to the Faculdade de Odontologia de Piracicaba (FOP), Universidade Estadual de Campinas (UNICAMP), for the support provided during this study. Appreciation is also extended to the Graduate Studies Committee for their administrative and academic assistance throughout the project. The authors are grateful to Prof. Dr. Rodney Alexandre Ferreira Rodrigues (Natural Products Chemistry Division, Multidisciplinary Center of Chemical, Biological, and Agricultural Research (CPQBA), UNICAMP, Paulínia 13148-218, São Paulo, Brazil) for the Acmella oleracea extract donation. Footnotes AUTHOR CONTRIBUTIONS: Michael Henrique Araujo Monteiro: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing.Josilanny Araujo de Souza Alencar: Formal analysis, Investigation, Methodology, Project administration, Writing – original draft, Writing – review & editing.Victor Augusto Benedicto dos Santos: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Resources, Software, Validation, Visualization, Writing – original draft, Writing – review & editing.Francisco Carlos Groppo: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Resources, Software, Supervision, Validation, Visualization, Writing – review & editing.Camila Batista da Silva de Araujo Candido: Conceptualization, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Supervision, Visualization, Writing – original draft, Writing – review & editing.Sidney Raimundo Figueroba: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing. Michael Henrique Araujo Monteiro: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing. Michael Henrique Araujo Monteiro: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing. Josilanny Araujo de Souza Alencar: Formal analysis, Investigation, Methodology, Project administration, Writing – original draft, Writing – review & editing. Josilanny Araujo de Souza Alencar: Formal analysis, Investigation, Methodology, Project administration, Writing – original draft, Writing – review & editing. Victor Augusto Benedicto dos Santos: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Resources, Software, Validation, Visualization, Writing – original draft, Writing – review & editing. Victor Augusto Benedicto dos Santos: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Resources, Software, Validation, Visualization, Writing – original draft, Writing – review & editing. Francisco Carlos Groppo: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Resources, Software, Supervision, Validation, Visualization, Writing – review & editing. Francisco Carlos Groppo: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Resources, Software, Supervision, Validation, Visualization, Writing – review & editing. Camila Batista da Silva de Araujo Candido: Conceptualization, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Supervision, Visualization, Writing – original draft, Writing – review & editing. Camila Batista da Silva de Araujo Candido: Conceptualization, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Supervision, Visualization, Writing – original draft, Writing – review & editing. Sidney Raimundo Figueroba: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing. Sidney Raimundo Figueroba: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing. DECLARATION OF INTERESTS: The authors declare no conflict of interest. FUNDING: This study was supported by the Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP; grant number 2023/15414-7) and the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Brazil, Finance Code 001. DATA AVAILABILITY De-identified individual participant data, statistical code, and the full trial protocol, including the prespecified statistical analysis plan, are available from the corresponding author upon request. References Associated Data Data Availability Statement De-identified individual participant data, statistical code, and the full trial protocol, including the prespecified statistical analysis plan, are available from the corresponding author upon request.